Cart
sales@molnova.com
Home - Products - GPCR/G Protein - Glucagon Receptor - V-0219

V-0219

CAS No. 878453-71-5

V-0219( —— )

Catalog No. M28512 CAS No. 878453-71-5

V-0219 is a positive allosteric modulator of GLP-1 and can be used in studies about obesity-associated diabetes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 191 Get Quote
10MG 327 Get Quote
25MG 604 Get Quote
50MG 906 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    V-0219
  • Note
    Research use only, not for human use.
  • Brief Description
    V-0219 is a positive allosteric modulator of GLP-1 and can be used in studies about obesity-associated diabetes.
  • Description
    V-0219 is a positive allosteric modulator of GLP-1 and can be used in studies about obesity-associated diabetes.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Glucagon Receptor
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    878453-71-5
  • Formula Weight
    410.43
  • Molecular Formula
    C20H25F3N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (243.65 mM)
  • SMILES
    FC(F)(F)C=1C=CC(=CC1)C2=NOC(=N2)CN3CCCC(C3)CN4CCOCC4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • GLP-1R agonist 3

    GLP-1R agonist 3 is a potent imidazole derivative and GLP-1R agonist with demonstrated research potential in diabetes. [Thickened]

  • HAEGTFTSDVS

    HAEGTFTSDVS is the first N-terminal 1-11 residues of GLP-1 peptide.

  • des-His1-[Glu9]-Gluc...

    Glucagon receptor antagonist (pA2 = 7.2 for inhibition of glucagon-induced adenylyl cyclase activation in rat liver membranes); displays no agonist activity. Enhances glucose-stimulated pancreatic insulin release in vitro. Blocks added glucagon-induced hyperglycemia in normal rabbits without affecting glycogenolysis in vivo. Also blocks endogenous glucagon-induced hyperglycemia in streptozocin diabetic rats.

Sign In Join Free